iPS-derived cardiomyocytes(Osaka University)

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameiPS-derived cardiomyocytes(Osaka University)

Drug Alias NameHuman (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsMyocardial Ischemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesOsaka University

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesOsaka University

Active IndicationsN/A

Inactive IndicationsMyocardial Ischemia

ATC CodeN/A